Review





Similar Products

86
Merck & Co pf 573 228 ifak
Pf 573 228 Ifak, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/228+573+ifak+pf/pm41063119-51-3-11
Average 86 stars, based on 1 article reviews
pf 573 228 ifak - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

95
Selleck Chemicals pf 573 228
Pf 573 228, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/PF-573228/pm40223421-206-18-20
Average 95 stars, based on 1 article reviews
pf 573 228 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

95
MedChemExpress pf 573 228
Pf 573 228, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/PF-573228/10__5812_slash_jjm___160281-51-1-8
Average 95 stars, based on 1 article reviews
pf 573 228 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

90
Millipore fak inhibitor pf-228
Fak Inhibitor Pf 228, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/pf573228/pm36054607-50-16-21
Average 90 stars, based on 1 article reviews
fak inhibitor pf-228 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Millipore pf-573-228
A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 <t>µM</t> <t>of</t> <t>PF-573-228</t> for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.
Pf 573 228, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/pf573+228/pmc03267729-229-39-40
Average 90 stars, based on 1 article reviews
pf-573-228 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

95
MedChemExpress fak inhibitors pf573 228
A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 <t>µM</t> <t>of</t> <t>PF-573-228</t> for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.
Fak Inhibitors Pf573 228, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/PF-573228/pm34338598-205-0-12
Average 95 stars, based on 1 article reviews
fak inhibitors pf573 228 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

90
Pfizer Inc pf-573-228
A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 <t>µM</t> <t>of</t> <t>PF-573-228</t> for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.
Pf 573 228, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/pf+573+228/pmc08564185-177-0-3
Average 90 stars, based on 1 article reviews
pf-573-228 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

95
MedChemExpress fak inhibitors pf 573 228
A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 <t>µM</t> <t>of</t> <t>PF-573-228</t> for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.
Fak Inhibitors Pf 573 228, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/PF-573228/pmc08331038-216-0-12
Average 95 stars, based on 1 article reviews
fak inhibitors pf 573 228 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

95
Selleck Chemicals pf 573228 pf 228
A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 <t>µM</t> <t>of</t> <t>PF-573-228</t> for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.
Pf 573228 Pf 228, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-228/PF-573228/pm32452639-14-36-55
Average 95 stars, based on 1 article reviews
pf 573228 pf 228 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 µM of PF-573-228 for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.

Journal: PLoS ONE

Article Title: Injection of Pseudomonas aeruginosa Exo Toxins into Host Cells Can Be Modulated by Host Factors at the Level of Translocon Assembly and/or Activity

doi: 10.1371/journal.pone.0030488

Figure Lengend Snippet: A/ VD3-differentiated HL-60 cells were exposed to 10 µM of cytochalasin D (CytoD), 10 µM of latrunculin B (LtrB) or 50 nM of Wortmannin for 30 min prior and during infection, or to 2 µM of TAT-C3 toxin, 100 µM of LY-294002, 12 µM of genistein, 10 µM of PP2, and 10 µM of PF-573-228 for 120 min prior and during a 3 h infection period at MOI 10 with the PAO1ΔSTY-SBlaR146A strain. The percentage of injection-positive cells was evaluated by flow cytometry. B/ Eukaryotic plasma membranes were purified by fractionation on sucrose gradient, after infection of cells pre-treated with inhibitors as above. Proteins were analysed by immunoblotting using anti-PopB. Ni : non-infected VD3-differentiated HL-60 cells, CTRL: infected VD3-differentiated HL-60 cells without inhibitor. C/ The ability of PAO1ΔSTY-SBlaR146A strain to secrete ExoS-Bla in vitro was assayed for each inhibitor modifying injection by immunoblotting of total secreted ExoS-Bla protein using the anti-ß-lactamase antibody. Pa: supernatant of T3SS non-induced P.aeruginosa , IPa: supernatant of T3SS induced P. aeruginosa without inhibitor.

Article Snippet: Cells were also exposed to either 100 µM of ROCK inhibitor Y-27632, 2.5 nM of Toxin B from Clostridium difficile (Sigma Chemical Co), 2 µM of TAT-C3 toxin from Clostridium botulinum (Cytoskeleton), 10 µM of PP2, 10 µM of PF-573-228 (Calbiochem), 100 µM of LY-294002 (Sigma Chemical Co) or 12 µM of Genistein (Sigma Chemical Co) for 120 min prior to and during infection in a humidified atmosphere with 5% CO 2 at 37°C.

Techniques: Infection, Injection, Flow Cytometry, Purification, Fractionation, Western Blot, In Vitro